Trial Profile
A Phase 1, Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CA-170 in Patients With Advanced Tumors and Lymphomas
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs CA 170 (Primary)
- Indications Lymphoma; Malignant-mesothelioma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Curis
- 24 Jun 2020 Status changed from active, no longer recruiting to completed.
- 05 Nov 2019 According to a Curis media release, the company does not intend to to enroll additional patients in this study. The Company plans to further evaluate the translational science and clinical pharmacodynamics of CA-170, in addition to patient data from this study, to assess the potential of future clinical studies of CA-170.
- 05 Nov 2019 According to a Curis media release, results from this study were presented at the Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting.